MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,818.93
+0.58%
NASDAQ 100
$31,224.47
+0.48%
DOW JONES
$51,521.00
+0.49%
NASDAQ Composite
$27,599.79
+0.45%
RUSSELL 2000
$2,813.40
-0.72%
CBOE VIX
$15.01
-3.29%
Sector Heatmap
Technology+0.53%
Financials+0.24%
Healthcare-0.17%
Consumer Cycl+1.20%
Consumer Staples+0.90%
Energy+0.47%
Industrials+0.87%
Materials+0.46%
Real Estate+1.06%
Utilities+2.98%
Comm Services+0.04%
MIRM — Mirum Pharmaceuticals, Inc. Common Stock
NasdaqMirum Pharmaceuticals, Inc. Common Stock
$79.25
-2.18(-2.68%)
- O
- 81.94
- H
- 81.94
- L
- 77.78
- V
- 1.14M
⏱️ End-of-day dataAs of Oct 6, 2026
Chart
About MIRM
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateJul 18, 2019
Employees433
Stock ExchangeNasdaq
Ticker SymbolMIRM
Websitehttps://www.mirumpharma.com
Key Financial Statistics
| Market Cap | $5.38B |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $63.23 - $130.00 |
| 52-Week Avg Volume | 808.7K |
| VWAP | $79.34 |
| Transactions | 18,440 |
| Total Recorded Bars | 1,815 days |